A Randomized, Observer-Blind, Controlled Trial of the Traditional Chinese Medicine Yi-Gan San for Improvement of Behavioral and Psychological Symptoms and Activities of Daily Living in Dementia Patients

2005 ◽  
Vol 66 (02) ◽  
pp. 248-252 ◽  
Author(s):  
Koh Iwasaki ◽  
Takuma Satoh-Nakagawa ◽  
Masahiro Maruyama ◽  
Yasutake Monma ◽  
Miyako Nemoto ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Activities Of Daily Living ◽  
Daily Living ◽  
Psychological Symptoms ◽  
Controlled Trial ◽  
Dementia Patients ◽  
Behavioral And Psychological Symptoms

Azelastine hydrochloride on behavioral and psychological symptoms and activities of daily living in dementia patients

2008 ◽  
Vol 8 (1) ◽  
pp. 59-61 ◽  
Author(s):  
Aiko Hatakeyama ◽  
Masahiko Fujii ◽  
Reiko Hatakeyama ◽  
Yumiko Fukuoka ◽  
Takuma Satoh-Nakagawa ◽  
...  
Keyword(s):  
Activities Of Daily Living ◽  
Daily Living ◽  
Psychological Symptoms ◽  
Dementia Patients ◽  
Behavioral And Psychological Symptoms

Combined Exercise and Cognitive Training System for Dementia Patients: A Randomized Controlled Trial

2018 ◽  
Vol 45 (5-6) ◽  
pp. 318-325 ◽  
Author(s):  
Hitoshi Okamura ◽  
Michiaki Otani ◽  
Naonori Shimoyama ◽  
Takayuki Fujii
Keyword(s):  
Activities Of Daily Living ◽  
Cognitive Training ◽  
Daily Living ◽  
Controlled Trial ◽  
Intervention Group ◽  
Training System ◽  
Control Group ◽  
Combined System ◽  
Combined Exercise ◽  
Dementia Patients

Background/Aims: We investigated the efficacy of a combined exercise and cognitive training system that we devised for improvement of attention and concentration, cognition, and activities of daily living in older adults with dementia. Methods: A total of 100 dementia patients were randomly assigned to an intervention group or a control group. The intervention group was subjected to a combined exercise and cognitive training for 6 consecutive weeks. Evaluations were performed using the Trail Making Test-Part A, the Mini-Mental State Examination, and an N-type activities of daily living evaluation scale for the elderly. Results: A comparison of the changes in scores on the evaluation scales between the intervention group and the control group showed significant interactions for all scores. Conclusions: The combined system is effective in increasing attention and concentration and improving cognitive function and activities of daily living in dementia patients.

Discussion 1

2000 ◽  
Vol 12 (S1) ◽  
pp. 73-75
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activities Of Daily Living ◽  
Preliminary Data ◽  
Daily Living ◽  
Psychological Symptoms ◽  
The Third ◽  
Behavioral And Psychological Symptoms

Dr. Grossberg began the discussion by sharing preliminary data from a study designed to determine risk factors for institutionalization in patients with autopsy-confirmed Alzheimer's disease (AD). Initial findings from this study, which enrolled 100 patients, indicate that the principal predictor of institutionalization is behavioral and psychological symptoms of dementia (BPSD), principally agitation, aggressiveness, and problem wandering. Difficulty with activities of daily living, especially related to continence and hygiene issues, was the second most common predictor of institutionalization. The third most common predictor was lack of a caregiver, either because of death or because of other reasons.

scholarly journals Traditional Chinese Medicine Improves Activities of Daily Living in Parkinson's Disease

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Weidong Pan ◽  
Shin Kwak ◽  
Yun Liu ◽  
Yan Sun ◽  
Zhenglong Fang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Activities Of Daily Living ◽  
Power Law ◽  
Daily Living ◽  
Rating Scale ◽  
Drug Efficacy ◽  
Disease Rating

We evaluated the effects of a traditional Chinese medicine (TCM), named Zeng-xiao An-shen Zhi-chan 2 (ZAZ2), on patients with Parkinson's disease (PD). Among 115 patients with idiopathic PD enrolled (mean age, 64.7 ± 10.2 years old), 110 patients (M = 65, F = 45; mean age, 64.9 ± 10.7 years old) completed the study. Patients took either ZAZ2 () or placebo granule () in a blind manner for 13 weeks while maintaining other anti-Parkinson medications unchanged. All participants wore a motion logger, and we analyzed the power-law temporal autocorrelation of the motion logger records taken on 3 occasions (before, one week, and 13 weeks after the drug administration). Drug efficacy was evaluated with the conventional Unified Parkinson Disease Rating Scale (UPDRS), as well as the power-law exponentα, which corresponds to the level of physical activity of the patients. ZAZ2 but not placebo granule improved the awake-sleep rhythm, the UPDRS Part II, Part II + III, and Part IV scores, and theαvalues. The results indicate that ZAZ2 improved activities of daily living (ADL) of parkinsonism and, thus, is a potentially suitable drug for long-term use.

scholarly journals Yokukansankachimpihange Is Useful to Treat Behavioral/Psychological Symptoms of Dementia

2021 ◽  
Vol 7 ◽  
Author(s):  
Eiichi Katsumoto ◽  
Toru Ishida ◽  
Kenji Kinoshita ◽  
Miho Shimizu ◽  
Toshihito Tsutsumi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Daily Living ◽  
Rating Scale ◽  
Psychological Symptoms ◽  
Gastrointestinal Symptoms ◽  
Multicenter Studies ◽  
Dementia Patients ◽  
Loss Of Appetite ◽  
Behavioral And Psychological Symptoms

Yokukansankachimpihange is a Japanese herbal medicine reported to benefit anxiety and sleep disorders, and it has recently been introduced to treat behavioral and psychological symptoms of dementia. There are no multicenter studies of its effectiveness regarding dementia in Japan, and this study's main objective was to clarify the effects of Yokukansankachimpihange on behavioral and psychological symptoms of dementia in a sample of patients from multiple healthcare centers. Nine facilities affiliated with Osaka Association of Psychiatric Clinics participated in November 2013 through April 2015 and provided 32 Alzheimer's disease patients to whom Yokukansankachimpihange was orally administered for 8 weeks. During the study, the patients continued their regular medication regimens. Behavioral and psychological symptoms of dementia (Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD]), core symptoms [Mini-Mental State Examination (MMSE)], activities of daily living [Nishimura Activity of Daily Living Scale (N-ADL)], and gastrointestinal symptoms (nausea/vomiting, loss of appetite, gastric discomfort, constipation, and diarrhea) were measured at baseline, after 4 weeks of treatment and after 8 weeks of treatment. Yokukansankachimpihange was orally administered at a dosage of 7.5 g twice daily before or between meals for 8 weeks. The Behave-AD mean score significantly improved after 8 weeks of treatment. There were no significant changes in MMSE, N-ADL, or gastrointestinal symptoms; however, decreased gastrointestinal scores were observed after 8 weeks. There were no side effects related to Yokukansankachinpihange. Pharmaceutical treatments are important for treating behavioral and psychological symptoms of dementia, and this study confirmed Yokukansankachimpihange's efficacy for treating Alzheimer's disease. Because the aggressiveness and sleep disorder components of the Behave-AD construct were the symptoms most improved and those symptoms are known to significantly burden dementia patients' caregivers, Yokukansankachimpihange's efficacy might indirectly relieve these caregivers' burden of care.

Sign in / Sign up

Export Citation Format

Share Document